Insight and Control of Infectious Disease in Global Scenario

Abstract

users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source.As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. NoticeStatements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book.

Synthesis and Analysis of Properties of an Immunogenic Fragment from NS4A Polypeptide of Hepatitis C Virus

“…Currently, researchers continue to search for new drugs or to modify existing drugs to increase the effectiveness or minimize side effects [1][2][3][4]. Synthetic peptides containing amino acid sequences of antigen epitopes can purposefully activate cells of the immune system [5][6][7][8]. To create a proper immunogen, it is necessary to use a peptide containing not only a B-cell antigenic determinant, but also a T-helper epitope, as well as a properly selected adjuvant, which will increase immunogenicity and form immunological memory [6,[8][9][10][11][12][13].…”

“…One of the ways of such blocking is binding to antibodies specific to the site of interaction of the NS4A polypeptide with the NS3 protease domain. For the production of such antibodies, it is necessary to formulate an immunogenic construct containing both the NS4A polypeptide region responsible for interaction with the NS3 protease and the B-cell and Thelper epitopes [6,8,12]. Since the NS4A polypeptide contains experimentally identified B-cell and T-helper epitopes, which are fully or partially included in the site of interaction with NS3 [15,16], the immunogenic construct can be a fragment of the NS4A polypeptide containing both the site of interaction with NS3, and the indicated epitopes.…”